CAS: 22619-35-8; Tioclomarol
该化合物是一种主要用于治疗和预防血栓塞病的抗凝胶药物,它作为维生素K敌国,抑制了正常血液凝固所必需的依赖维生素K的凝块因素合成,其特点是它能够减少血凝块的危险,使其在临床环境中具有价值,特别是对于患有深血栓或肺栓塞等病症的病人来说尤其如此.Tioclomarol一般是口服的,其半衰期相对较长,在许多情况下可以每天服一次药,其药理学可能受到各种因素的影响,包括饮食和同时服药,因此需要仔细监测凝固参数,例如血清时间或国际正常比率.虽然有效,但磷酸也可能造成出血的危险,使用它需要彻底评估病人的历史和可能的药物相互作用.与任何抗凝固剂一样,其临床应用中,治疗功效和安全之间的平衡至关重要.
- 英文名称Tioclomarol
- 中文名称噻氯香豆素
- IUPAC名称3-(3-(4-chlorophenyl)-1-(5-chlorothiophen-2-yl)-3-hydroxypropyl)-4-hydroxy-2H-chromen-2-one
- 其它别名3-[1-(5-Chloro-2-Thienyl)-3-Hydroxy-3-(4-Chlorophenyl)Propyl]-4-Hydroxycoumarin; Tioclomarol; 3-[3-(4-Chlorophenyl)-1-(5-Chloro-2-Thienyl)-3-Hydroxypropyl]-4-Hydroxy-2H-1-Benzopyran-2-One; 3-[5-Chloro-α-(P-Chloro-β-Hydroxyphenethyl)-2-Thenyl]-4-Hydroxy-Coumarin; Apegmone; 2H-1-Benzopyran-2-One, 3-[3-(4-Chlorophenyl)-1-(5-Chloro-2-Thienyl)-3-Hydroxypropyl]-4-Hydroxy-
- CAS编号22619-35-8
- MFCD编号:MFCD00865276
- EINECS号:245-132-1
- FDA UNII编号:E5B7C16LFK
- 分子式:C22H16Cl2O4S分子量:447.34
- 产品CID: 1164614
- 产品分类有机原料 → 苯丙烷和聚酮 → 香豆素及其衍生物
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2902600000-乙苯
2903919090-氯苯
2905121000-正丙醇
2906210000-苄醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
专利号:US-10814013-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:AU-2007308022-A2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:AU-2007308022-A1
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:US-2008107598-A1
优先权日:2006-10-05
标 题:Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications
专利号:AU-2007308022-B2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2003).
📝 需求与反馈
尽可能描述清楚需求与问题信息
